Pharmaceutical Business Review
Return to: PBR Home | Companies

Seattle Genetics Inc

Seattle Genetics Inc
21823 - 30th Drive S.E.
Bothell
United States of America
Phone: 1 425 5274000
www.seattlegenetics.com

No. employees: 1,100
Turnover: 482.25 (US$m)
Financial year end: December

Company Overview

Top Competitors


Key Employees

Clay B. Siegall, Ph.D.

Chief Executive Officer, President, Chairman, Executive Board

Felix J. Baker, Ph.D.

Director, Non Executive Board

Daniel G. Welch

Director, Non Executive Board

Marc E. Lippman, M.D.

Director, Non Executive Board

David W. Gryska

Director, Non Executive Board

Nancy A. Simonian, M.D.

Director, Non Executive Board

John A. Orwin

Director, Non Executive Board

Srinivas Akkaraju, M.D., Ph.D

Director, Non Executive Board

Elaine Waller

Executive Vice President - Regulatory Affairs and Clinical Development Operations, Senior Management

Todd E. Simpson

Chief Financial Officer, Senior Management

Vaughn B. Himes, Ph.D.

Chief Technical Officer, Senior Management

Darren Cline

Executive Vice President - Commercial, Senior Management

Jean I. Liu

General Counsel, Executive Vice President - Legal Affairs, Senior Management

Christopher Pawlowicz

Executive Vice President - Human Resources, Senior Management

Roger D. Dansey

Chief Medical Officer, Senior Management

Locations/Subsidiaries


21823 - 30th Drive S.E. ,
Bothell,
Washington,
United States of America
Phone: 1 425 5274000

SeaGen Canada Inc

Canada

SeaGen International GmbH

Zug,
Switzerland

Seattle Genetics UK, Ltd.

United Kingdom

SeaGen Inc

United States of America

SeaGen International Holdings, Inc.

Washington,
United States of America

SeaGen US Holdings Inc

United States of America

Products/Services


Products:

  • Adcetris (brentuximab vedotin) - Relapsed Hodgkin Lymphoma and Relapsed Systemic Anaplastic Large Cell Lymphoma
  • Product Pipeline:
  • Brentuximab Vedotin - Cutaneous T-cell Lymphoma
  • Tisotumab Vedotin - Solid Tumors
  • SGN-CD19A (denintuzumab mafodotin) - Diffuse Large B-cell Lymphoma
  • ASG-22ME (enfortumab vedotin) - Metastatic Urothelial Cancer
  • SGN-LIV1A - Metastatic Breast Cancer
  • SEA-CD40 - Metastatic or Unresectable Solid Tumors; Hematologic Malignancies
  • SGN-CD19B - Relapsed Non-Hodgkin Lymphomas
  • SGN-CD123A - Acute Myeloid Leukemia
  • SGN-CD352A - Multiple Myeloma
  • SGN-2FF - Solid Tumors